TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11069341

Group type: EXPERIMENTAL
Intervention: Subcutaneous tunnelling with a loop for epidural catheter fixation (n = 34)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Simple loop of epidural catheter left over the skin (Control group, n = 34)
Number of subjects: 68
Study: 8709402

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Pegorgotein 10 000 U/kg
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Pegorgotein 20 000 U/kg
Number of subjects: 463
Study: 1567042

Group type: EXPERIMENTAL
Intervention: Promethazine (0.625 mg/PCA dose, average of 17.6 mg/24 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (PCA with morphine only, 1.5 mg, 6-min lockout interval)
Number of subjects: 0
Study: 3901826

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 650 mg daily postoperatively
Number of subjects: 93

Group type: COMPARATOR
Intervention: No aspirin (NASA)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Overall grafts (both ASA and NASA)
Number of subjects: 93
Study: 30515560

Group type: EXPERIMENTAL
Intervention: SwallowIT-assisted therapy (n=26)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Clinician-directed therapy (n=26)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Patient-directed therapy (n=27)
Number of subjects: 79
Study: 29696707

Group type: EXPERIMENTAL
Intervention: vitamin D3 (5000 IU daily) + phenylbutyrate (2 × 500 mg daily)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study: 28446396

Group type: EXPERIMENTAL
Intervention: Group T1 (ropivacaine for thoracic paravertebral block)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group T2 (ropivacaine and sufentanil for thoracic paravertebral block)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group C (control)
Number of subjects: 60
Study: 24448512

Group type: EXPERIMENTAL
Intervention: Perineural ropivacaine 0.4%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 60
Study: 22524447

Group type: EXPERIMENTAL
Intervention: Cisatracurium besylate therapy within 2 days of ARDS onset
Number of subjects: 339

Group type: COMPARATOR
Intervention: Patients with microbiologically documented bacterial VAP
Number of subjects: 339

Group type: COMPARATOR
Intervention: Patients without VAP
Number of subjects: 339

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 339

Group type: COMPARATOR
Intervention: Tracheostomy, enteral nutrition, and use of a subglottic secretion-drainage device
Number of subjects: 339
Study: 19910624

Group type: EXPERIMENTAL
Intervention: IV propofol
Number of subjects: 80

Group type: COMPARATOR
Intervention: sevoflurane
Number of subjects: 80
Study: 18366490

Group type: EXPERIMENTAL
Intervention: Sublingual administration of misoprostol (400 microg three‐hourly, up to a maximum of five doses over 24 h)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Vaginal administration of misoprostol (400 microg three‐hourly, up to a maximum of five doses over 24 h)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Sublingual administration of misoprostol
Number of subjects: 300

Group type: COMPARATOR
Intervention: Vaginal administration of misoprostol
Number of subjects: 300
Study: 16123481

Group type: EXPERIMENTAL
Intervention: Biofeedback (electromyograph and thermal) and relaxation (10 sessions)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Education (3 sessions)
Number of subjects: 39
Study: 11873073

Group type: EXPERIMENTAL
Intervention: Efavirenz-containing regimen (group 1; 51 patients)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Protease inhibitor-containing regimen (group 2; 49 patients)
Number of subjects: 100
Study: 10202784

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy, allogeneic or autologous bone marrow transplantation (BMT)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Randomized disclosure of collected information to staff
Number of subjects: 179
Study: 7586246

Group type: EXPERIMENTAL
Intervention: Streptokinase/subcutaneous heparin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination thrombolytic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary intracranial hemorrhage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonhemorrhagic infarctions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate or severe residual deficits
Number of subjects: 0
Study: 2154430

Group type: EXPERIMENTAL
Intervention: Azithromycin (250 mg bd on day 1 and 250 mg once daily on days 2-5)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Erythromycin (500 mg every 6 h for seven days)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g single dose or 500 mg single dose on day 1 and 250 mg once daily on days 2 and 3)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Doxycycline (100 mg every 12 h for seven days)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Azithromycin (3-day regimen)
Number of subjects: 190
Study: 426993

Group type: EXPERIMENTAL
Intervention: Pancuronium 0.02‐0.08 mg kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.003 mg kg‐1 plus droperidol 0.15 mg kg‐1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fentanyl 0.003 mg kg‐1
Number of subjects: 0
Study: 31422365

Group type: EXPERIMENTAL
Intervention: Immersive VR safety training alone
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Lecture‐based safety training alone
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Combined immersive VR safety training and HF Tool training
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Combined lecture‐based safety training and HF Tool training
Number of subjects: 130
Study: 31652899

Group type: EXPERIMENTAL
Intervention: Diet based on the 2010 Dietary Guidelines for Americans (DGA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Typical American diet (TAD)
Number of subjects: 0
Study: 28817507

Group type: EXPERIMENTAL
Intervention: Deferred consent
Number of subjects: 68

Group type: COMPARATOR
Intervention: Prior informed consent
Number of subjects: 68
Study: 25496088

Group type: EXPERIMENTAL
Intervention: Short-Term Assessment of Risk and Treatability (START)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Structured Professional Judgment (SPJ)
Number of subjects: 188
Study: 23517287

Group type: EXPERIMENTAL
Intervention: pegylated‐IFNα2a weekly or albumin‐IFNα2b every 2 weeks for up to 24 weeks
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 869
Study: 21210611

Group type: EXPERIMENTAL
Intervention: Didactic plus role-play
Number of subjects: 115

Group type: COMPARATOR
Intervention: Didactic instruction alone
Number of subjects: 115
Study: 18364324

Group type: EXPERIMENTAL
Intervention: Pineapple
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Papaya
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Watermelon
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Durian
Number of subjects: 10

Group type: COMPARATOR
Intervention: Glucose (reference food)
Number of subjects: 10
Study: 16287396

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy for Sexual Abuse Survivors (CPT‐SA)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Minimal Attention (MA)
Number of subjects: 71
Study: 12147834

Group type: EXPERIMENTAL
Intervention: Dietary fecal tagging (FT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard non-FT colonic cleansing
Number of subjects: 100
Study: 10824344

Group type: EXPERIMENTAL
Intervention: Use of New Zealand cardiovascular risk tables
Number of subjects: 0
Study: 8788692

Group type: EXPERIMENTAL
Intervention: Day treatment (intensive seven-day-a-week neurobehavioral treatment model program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional outpatient treatment (conventional five-day-a-week program)
Number of subjects: 0
Study: 2405746

Group type: EXPERIMENTAL
Intervention: Inhaled pirbuterol
Number of subjects: 133

Group type: COMPARATOR
Intervention: Metaproterenol
Number of subjects: 133
Study: 155297

Group type: EXPERIMENTAL
Intervention: Combination of beta 2-sympathomimetic (salbutamol or fenoterol) and SCH 1000
Number of subjects: 33

Group type: COMPARATOR
Intervention: SCH 1000 alone
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: SCH 1000
Number of subjects: 33
Study: 31076365

Group type: EXPERIMENTAL
Intervention: Trebananib plus carboplatin and paclitaxel
Number of subjects: 1015

Group type: COMPARATOR
Intervention: Placebo plus carboplatin and paclitaxel
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Trebananib
Number of subjects: 1015

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1015
Study: 29235507

Group type: EXPERIMENTAL
Intervention: Liraglutide (GLP-1 analog), 6 months treatment
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 25539240

Group type: EXPERIMENTAL
Intervention: IV hyoscine butylbromide before examination with manual carbon dioxide insufflation
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Automated carbon dioxide insufflation (no bowel relaxant)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Combined (hyoscine butylbromide before examination with automated carbon dioxide insufflation)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control (no bowel relaxant and IV saline placebo before CT colonography with manual carbon dioxide insufflation)
Number of subjects: 224
Study: 23886886

Group type: EXPERIMENTAL
Intervention: Action Observation Therapy (AOT) - observing video sequences of unimanual or bimanual goal-directed actions for 1 hour per day for 3 weeks followed by execution of observed actions
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group - performed the same actions but watched computer games instead of action videos
Number of subjects: 24
Study: 21402628

Group type: EXPERIMENTAL
Intervention: 24% sucrose solution orally
Number of subjects: 330

Group type: COMPARATOR
Intervention: 1 g of liposomal lidocaine cream topically
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: sucrose and liposomal lidocaine
Number of subjects: 330
Study: 19359148

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (12.3 mmol or 300 mg of elemental magnesium in the form of magnesium oxide, n=75)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo (n=80)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (subgroup analysis, n=8, 27, and 24 for different BP categories)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo (subgroup analysis, n=16, 29, and 25 for different BP categories)
Number of subjects: 155
Study: 17349076

Group type: EXPERIMENTAL
Intervention: Lightly cooked broccoli (microwaved 2.0 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fully cooked broccoli (microwaved 5.5 min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Meat-containing meal with mustard (3 g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non meat-containing meal with mustard (3 g)
Number of subjects: 12
Study: 15035837

Group type: EXPERIMENTAL
Intervention: UltraCision harmonic scalpel (UHS)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional clamp-and-tie technique
Number of subjects: 200
Study: 11392607

Group type: EXPERIMENTAL
Intervention: rhG‐CSF (filgrastim)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 10356434

Group type: EXPERIMENTAL
Intervention: Dental Anxiety Scale (DAS)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Experience with dental injections
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: DAS scores
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Medical avoidance and anxiety scores
Number of subjects: 350
Study: 7989975

Group type: EXPERIMENTAL
Intervention: Radioiodine therapy (0.85‐9.55 GBq or 23‐258 mCi of 131I)
Number of subjects: 87
Study: 2670220

Group type: EXPERIMENTAL
Intervention: ACE inhibitors (captopril, enalapril, quinapril)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0
Study: 30359869

Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 344

Group type: COMPARATOR
Intervention: Physical education control
Number of subjects: 344
Study: 28719834

Group type: EXPERIMENTAL
Intervention: d3-GHR group (d3/fl and d3/d3)
Number of subjects: 96

Group type: COMPARATOR
Intervention: fl/fl-GHR group
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: After one year of GH therapy
Number of subjects: 96
Study: 25150178

Group type: EXPERIMENTAL
Intervention: Bosentan treatment for 12 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 52
Study: 23571718

Group type: EXPERIMENTAL
Intervention: Rapid on-site cytologic evaluation (ROSE) during EBUS-TBNA
Number of subjects: 108

Group type: COMPARATOR
Intervention: Non-ROSE during EBUS-TBNA
Number of subjects: 108
Study: 21621796

Group type: EXPERIMENTAL
Intervention: HADS anxiety (HADS-A) score at baseline
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: HADS depression (HADS-D) score at baseline
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: HADS anxiety (HADS-A) score at six months
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: HADS depression (HADS-D) score over time
Number of subjects: 120
Study: 18327133

Group type: EXPERIMENTAL
Intervention: Vitrectomy with ILM peeling
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Vitrectomy with ILM peeling followed by IVTA injection
Number of subjects: 38

Group type: COMPARATOR
Intervention: Vitrectomy
Number of subjects: 38
Study: 16916051

Group type: EXPERIMENTAL
Intervention: Chronic active hepatitis C patients
Number of subjects: 100
Study: 11161933

Group type: COMPARATOR
Intervention: 12-lead ECG
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Body surface mapping
Number of subjects: 54
Study: 9678318

Group type: COMPARATOR
Intervention: Mattis Dementia Rating Scale Memory subscale (AD group)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Initiation/Perseveration subscale (LBV group)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Attention, Construction, Conceptualization subscales
Number of subjects: 46

Group type: COMPARATOR
Intervention: Construction subscale (mild-to-moderate dementia subgroup)
Number of subjects: 46
Study: 7977090

Group type: EXPERIMENTAL
Intervention: Felodipine, 5 mg once daily
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (ISMN), 20 mg twice daily
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 46

Group type: COMPARATOR
Intervention: ISMN
Number of subjects: 46
Study: 3197098

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (10 mg) + Acetylsalicylic acid (80 mg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 29468817

Group type: EXPERIMENTAL
Intervention: 500 mL regular coffee containing 34.8 μmol nicotinic acid (NA) and 0.58 μmol nicotinamide (NAM)
Number of subjects: 0
Study: 25834948

Group type: EXPERIMENTAL
Intervention: 10-mg idursulfase-IT
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 30-mg idursulfase-IT
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1-mg idursulfase-IT
Number of subjects: 16

Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: surgical revision/removal of the IDDD
Number of subjects: 16
Study: 24835417

Group type: EXPERIMENTAL
Intervention: EMD + DBBM
Number of subjects: 40

Group type: COMPARATOR
Intervention: CM + DBBM
Number of subjects: 40
Study: 22336901

Group type: EXPERIMENTAL
Intervention: Custom-made orthesis and shoes as part of a structured prevention program (Group B)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Standard treatment (Group A)
Number of subjects: 298
Study: 19892540

Group type: EXPERIMENTAL
Intervention: Tiotropium 18μg inhalation capsules once daily
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo inhalation capsules once daily
Number of subjects: 22
Study: 18375477

Group type: EXPERIMENTAL
Intervention: Plasma butyrylcholinesterase (BuChE) activity <600 mU/ml in chlorpyrifos poisoning
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Plasma butyrylcholinesterase (BuChE) activity <600 mU/ml in dimethoate poisoning
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: High organophosphorus (OP) concentration on admission
Number of subjects: 299
Study: 15976380

Group type: EXPERIMENTAL
Intervention: FENO group (n=39)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Symptom group (n=46)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 85
Study: 11430713

Group type: EXPERIMENTAL
Intervention: Group motor skill intervention, once weekly for 10 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control subgroup (no intervention), n = 20
Number of subjects: 37
Study: 9566656

Group type: EXPERIMENTAL
Intervention: Melatonin treatment (2.5 to 7.5 mg based on body weight)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Melatonin treatment
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 9
Study: 8110567

Group type: EXPERIMENTAL
Intervention: 1% ropivacaine 10 ml
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine 20 ml
Number of subjects: 91

Group type: COMPARATOR
Intervention: 0.5% bupivacaine 20 ml
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 91
Study: 3294080

Group type: EXPERIMENTAL
Intervention: Gastric bubble
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 23
Study: 31144121

Group type: EXPERIMENTAL
Intervention: Timed colonoscopy with fixed withdrawal times (Group A)
Number of subjects: 1149

Group type: COMPARATOR
Intervention: Conventional withdrawal (Group B)
Number of subjects: 1149

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1149
Study: 30296845

Group type: EXPERIMENTAL
Intervention: Group-Early Start Denver Model in inclusive setting
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Group-Early Start Denver Model in specialized setting
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Group-Early Start Denver Model (both settings)
Number of subjects: 44
Study: 27352003

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (50 μg kg−1) and midazolam (0.45 mg kg−1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Dexmedetomidine (30 μg kg−1), midazolam (0.45 mg kg−1) and butorphanol (0.25 mg kg−1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both protocols (DM and DMB)
Number of subjects: 16
Study: 25376431

Group type: EXPERIMENTAL
Intervention: Textured Tuohy needle
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Textured single-shot needle
Number of subjects: 144

Group type: COMPARATOR
Intervention: Smooth-surfaced Tuohy needle
Number of subjects: 144
Study: 23984433

Group type: EXPERIMENTAL
Intervention: High intensity interval exercise (HI‐IE)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Moderate intensity continuous exercise (MI‐CE)
Number of subjects: 15
Study: 19783056

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 308
Study: 19260398

Group type: EXPERIMENTAL
Intervention: Web-based course
Number of subjects: 147

Group type: COMPARATOR
Intervention: Traditional classroom teaching
Number of subjects: 147
Study: 17096616

Group type: EXPERIMENTAL
Intervention: Gain-framed heart disease prevention message
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Loss-framed heart disease prevention message
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Gain-framed message for women with parental risk factors
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Loss-framed message for women with parental risk factors
Number of subjects: 395
Study: 15677411

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) + Diet for 6 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Wait-List (WL) control group
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) + Diet
Number of subjects: 22
Study: 11350261

Group type: EXPERIMENTAL
Intervention: LCT (long chain triglycerides, corn oil)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: VLCT (very long chain triglycerides, fish oil)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: MCT (medium chain triglycerides) 15 mL h(‐1)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: MCT (medium chain triglycerides) 30 mL h(‐1)
Number of subjects: 7

Group type: COMPARATOR
Intervention: MCT (medium chain triglycerides)
Number of subjects: 7
Study: 9448125

Group type: EXPERIMENTAL
Intervention: Endoscopic balloon sphincteroplasty (EBS)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Endoscopic balloon sphincteroplasty (EBS) combined with laparoscopic cholecystectomy (LC)
Number of subjects: 33
Study: 7639370

Group type: EXPERIMENTAL
Intervention: Single injection of 25 mL of 0.75% bupivacaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Staged injection of 25 mL of 0.75% bupivacaine
Number of subjects: 30
Study: 30924845

Group type: EXPERIMENTAL
Intervention: Letter transposition (LT) technique with initial transpositions
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Letter transposition (LT) technique with internal transpositions
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Letter transposition (LT) technique with final transpositions
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Letter transposition (LT) technique
Number of subjects: 18
Study: 27885554

Group type: EXPERIMENTAL
Intervention: Active gum
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 57

Group type: COMPARATOR
Intervention: No gum
Number of subjects: 57
Study: 27470449

Group type: EXPERIMENTAL
Intervention: CTA and selective FFRCT (n = 297)
Number of subjects: 584

Group type: COMPARATOR
Intervention: Usual care (n = 287)
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: FFRCT (cost weight of zero)
Number of subjects: 584

Group type: COMPARATOR
Intervention: Usual care (cost weight of zero)
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: FFRCT (noninvasive stratum)
Number of subjects: 584

Group type: COMPARATOR
Intervention: Usual care (noninvasive stratum)
Number of subjects: 584
Study: 25170121

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) plus corticosteroids
Number of subjects: 372

Group type: COMPARATOR
Intervention: Corticosteroids alone (placebo)
Number of subjects: 372
Study: 22100189

Group type: EXPERIMENTAL
Intervention: Aquacel(®) Ag
Number of subjects: 40

Group type: COMPARATOR
Intervention: MEBO(®)
Number of subjects: 40